Mendel is mid-pivot. His capex sequencing improved sharply in 2025; his disclosure breadth has not kept pace. We rate the dossier B+ trending up, with two open governance items.
| Date | Action | Size | Our read | Outcome |
|---|---|---|---|---|
| 02·2026 | Capex reclassification — Plant 7 | $84M | Constructive · sequencing tracks | ▲ |
| 11·2025 | Buyback paused; capex stepped up | — | Defensible · we'd have done the same | ▲ |
| 06·2025 | Bolt-on · Cresswell Specialty (private) | $220M | Reasonable price · adjacent | → |
| 02·2025 | Refi · 5y senior · 6.4% | $600M | Average execution · windowed late | → |
| 10·2024 | Divestiture · West Texas aggregates | $310M | Right call · price okay, not great | → |
Mendel is the right operator for the pivot CLST is attempting. His SPEX track is closely-rhyming and his capex framework has tightened since arrival. Two reservations: (a) disclosure breadth on the segment build-out remains thin; we'd like more granularity by Q3 2026, and (b) the board's audit committee is one seat short of where we'd want it given the capex expansion.
— D. Halberd · Lead Analyst · Industrials